MTC
MCID: MDL022
MIFTS: 63

Medullary Thyroid Carcinoma, Familial (MTC) malady

Categories: Genetic diseases, Rare diseases, Gastrointestinal diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Medullary Thyroid Carcinoma, Familial

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 24GeneTests, 27GTR, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Medullary Thyroid Carcinoma, Familial:

Name: Medullary Thyroid Carcinoma, Familial 52
Medullary Thyroid Carcinoma 52 11 54 70 12 13
Familial Medullary Thyroid Carcinoma 11 24 54 13 68
Thyroid Carcinoma, Familial Medullary 52 11 50
Familial Medullary Thyroid Cancer 24 27
Thyroid Carcinoma, Medullary 48 27
Thyroid Medullary Carcinoma 11 13
Thyroid Cancer, Medullary 48 39
Mtc 54 70
 
Medullary Carcinoma of the Thyroid Gland 11
Ultimobranchial Thyroid Tumour 11
Medullary Carcinoma of Thyroid 68
Ultimobranchial Thyroid Tumor 11
Thyroid Carcinoma Medullary 50
Medullary Thyroid Cancer 48
Familial Mtc 54
Fmtc 24

Characteristics:

Orphanet epidemiological data:

54
medullary thyroid carcinoma:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (United States),1-9/1000000 (Europe); Age of onset: Adult
familial medullary thyroid carcinoma:
Inheritance: Autosomal dominant

HPO:

64
medullary thyroid carcinoma, familial:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 155240
Disease Ontology11 DOID:0050547, DOID:3973
MeSH39 C536914
NCIt45 C3879
MESH via Orphanet40 C536914, C536911
UMLS via Orphanet69 C0238462, C1833921
ICD10 via Orphanet31 C73
MedGen37 C1833921

Summaries for Medullary Thyroid Carcinoma, Familial

About this section
OMIM:52 Medullary thyroid carcinoma (MTC) is a malignant tumor of the calcitonin (114130)-secreting parafollicular C cells of... (155240) more...

MalaCards based summary: Medullary Thyroid Carcinoma, Familial, also known as medullary thyroid carcinoma, is related to ntrk1-related familial medullary thyroid carcinoma and multiple endocrine neoplasia iia, and has symptoms including Array, Array and Array. An important gene associated with Medullary Thyroid Carcinoma, Familial is RET (Ret Proto-Oncogene), and among its related pathways are Signaling events regulated by Ret tyrosine kinase and G-protein signaling_H-RAS regulation pathway. Affiliated tissues include thyroid, endothelial and liver, and related mouse phenotypes are muscle and neoplasm.

Disease Ontology:11 A follicular thyroid carcinoma that has material basis in parafollicular cells.

UniProtKB/Swiss-Prot:70 Medullary thyroid carcinoma: Rare tumor derived from the C cells of the thyroid. Three hereditary forms are known, that are transmitted in an autosomal dominant fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases and where MTC is the only clinical manifestation.

Wikipedia:71 Medullary thyroid cancer (MTC) is a form of thyroid carcinoma which originates from the parafollicular... more...

Related Diseases for Medullary Thyroid Carcinoma, Familial

About this section

Diseases in the Medullary Thyroid Carcinoma, Familial family:

Ntrk1-Related Familial Medullary Thyroid Carcinoma

Diseases related to Medullary Thyroid Carcinoma, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 109)
idRelated DiseaseScoreTop Affiliating Genes
1ntrk1-related familial medullary thyroid carcinoma12.0
2multiple endocrine neoplasia iia11.7
3thyroid cancer, monmedullary, 111.2
4multiple endocrine neoplasia iib11.1
5fasting plasma glucose level qtl 510.4NTRK1, RET
6endophthalmitis10.3CALCA, TG
7lung occult small cell carcinoma10.3CALCA, NTRK1, SST
8pemphigus foliaceus10.3CALCA, MEN1, SST
9wells-jankovic syndrome10.3CALCA, SST
10meigel disease10.3GDNF, RET
11adult ependymoblastoma10.3CALCA, CHGA, MEN1
12opioid abuse10.3CALCA, MEN1, RET
13vagneur triolle ripert syndrome10.3CEACAM5, CHGA
14alpha-heavy chain disease10.3CALCA, GAST
15nodular prostate10.3CALCA, RET, TG
16waardenburg syndrome, type 4a10.3EDNRB, RET
17spinal stenosis10.3CALCA, CHGA, SST
18vestibulocochlear nerve disease10.3GDNF, RET, SST
19cowper gland carcinoma10.3CHGA, MEN1, RET
20hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome10.3OSMR, RET
21uterine ligament cancer10.3MEN1, SST, SSTR2
22myoepithelial carcinoma10.3CHGA, NTRK1, SST
23connective tissue cancer10.3CALCA, GDNF, RET
24non-syndromic x-linked intellectual disability10.3CHGA, RET, SST
25ampulla of vater mucinous adenocarcinoma10.3CHGA, NTRK1, SSTR2
26vulvar keratoacanthoma-like carcinoma10.3CEACAM5, CHGA
27tmem70 defect10.3NKX2-1, RET, TG
28breast secretory carcinoma10.3CHGA, SST, SSTR2
29parachordoma10.3NKX2-1, RET, TG
30shprintzen-goldberg syndrome10.3EDNRB, GDNF, RET
31infertility10.3NKX2-1, RET, TG
32autoimmune hemolytic anemia10.3CALCA, RET, TG
33ariboflavinosis10.3EDNRB, GDNF, RET
34immune system organ benign neoplasm10.3MEN1, SST, TG
35spinal meningioma10.3EDNRB, GDNF, RET
36autoimmune pancreatitis10.3CHGA, GAST
37parathyroid carcinoma10.3CALCA, CHGA, MEN1, RET
38exanthema subitum10.2CALCA, NKX2-1, TG
39childhood teratocarcinoma of the testis10.2CALCA, CHGA, RET, TG
40cardioauditory syndrome of sanchez cascos10.2CALCA, CHGA, MEN1, SST
41neuritis10.2SST, SSTR2, SSTR5
42testicular trophoblastic tumor10.2CALCA, CEACAM5, CHGA
43chronic infections, due to mbl deficiency10.2EDNRB, GDNF, RET
44strabismus10.2CEACAM5, MEN1, TG
45rheumatic encephalitis10.2MEN1, SST, SSTR5
46skin pilomatrix carcinoma10.2EDNRB, GDNF, GFRA1, RET
47ascariasis10.2SST, SSTR2
48secondary syphilis10.2CHGA, GAST, SST
49brain edema10.2CHGA, GAST, SST
50gastrinoma10.2CALCA, NKX2-1, RET, TG

Graphical network of the top 20 diseases related to Medullary Thyroid Carcinoma, Familial:



Diseases related to medullary thyroid carcinoma, familial

Symptoms & Phenotypes for Medullary Thyroid Carcinoma, Familial

About this section

Symptoms by clinical synopsis from OMIM:

155240

Clinical features from OMIM:

155240

Human phenotypes related to Medullary Thyroid Carcinoma, Familial:

 54 64 (show all 14)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 medullary thyroid carcinoma64 54 Obligate (100%) HP:0002865
2 elevated calcitonin64 54 Very frequent (99-80%) HP:0003528
3 nodular goiter64 54 Very frequent (99-80%) HP:0005994
4 hyperhidrosis64 54 Frequent (79-30%) HP:0000975
5 diarrhea64 54 Frequent (79-30%) HP:0002014
6 dysphagia64 54 Frequent (79-30%) HP:0002015
7 lymphadenopathy64 54 Frequent (79-30%) HP:0002716
8 dysphonia64 54 Occasional (29-5%) HP:0001618
9 weight loss64 54 Occasional (29-5%) HP:0001824
10 pheochromocytoma64 54 Occasional (29-5%) HP:0002666
11 primary hyperparathyroidism64 54 Occasional (29-5%) HP:0008200
12 neoplasm of the skeletal system64 54 Occasional (29-5%) HP:0010622
13 abnormal liver parenchyma morphology64 54 Occasional (29-5%) HP:0030146
14 neoplasm of the lung64 54 Occasional (29-5%) HP:0100526

MGI Mouse Phenotypes related to Medullary Thyroid Carcinoma, Familial according to GeneCards Suite gene sharing:

41 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053699.9EDNRB, ESR2, GDNF, GFRA1, MEN1, NTRK1
2MP:00020069.4CALCB, EDNRB, ESR2, GAST, MEN1, NKX2-1
3MP:00053858.9CALCB, CCKBR, CHGA, EDNRB, ESR2, GDNF
4MP:00053878.8CCKBR, EDNRB, ESR2, GAST, GDNF, GFRA1
5MP:00053818.7CCKBR, EDNRB, ESR2, GAST, GDNF, GFRA1
6MP:00053678.6CALCB, CCKBR, CHGA, EDNRB, ESR2, GDNF
7MP:00053788.4CCKBR, CHGA, EDNRB, ESR2, GDNF, MEN1
8MP:00053798.3CCKBR, CHGA, EDNRB, ESR2, GAST, GDNF
9MP:00053868.1CALCB, CCKBR, EDNRB, ESR2, GDNF, GFRA1
10MP:00036317.8CALCB, CCKBR, EDNRB, ESR2, GDNF, GFRA1
11MP:00053767.2CALCB, CCKBR, CHGA, EDNRB, ESR2, GAST

Drugs & Therapeutics for Medullary Thyroid Carcinoma, Familial

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Cometriq16 44 CABOZANTINIB S-MALATE Exelixis November 2012
FDA Label: Cometriq
Disease/s that Drug Treats:thyroid cancer
Indications and Usage:16 COMETRIQ is a kinase inhibitor indicated for the treatment ofpatients with progressive, metastatic medullary thyroid cancer(MTC). (1)
DrugBank Targets:14 1. Hepatocyte growth factor receptor;2. Vascular endothelial growth factor receptor 2;3. Proto-oncogene tyrosine-protein kinase receptor Ret
Mechanism of Action:16 
Target: tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, and TIE-2
Action: inhibitor
FDA: In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosinekinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, and TIE-2.These receptor tyrosine kinases are involved in both normal cellular function and pathologicprocesses such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumormicroenvironment.
2
Vandetanib16 44 vandetanib AstraZeneca April 2011
FDA Label: -
Disease/s that Drug Treats:thyroid cancer
Indications and Usage:16 -
DrugBank Targets:14 1. Vascular endothelial growth factor A;2. Epidermal growth factor receptor;3. Protein-tyrosine kinase 6;4. Angiopoietin-1 receptor
Mechanism of Action:16 
Target: tyrosine kinases
Action: inhibitor
FDA: -

Drugs for Medullary Thyroid Carcinoma, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 194)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1tyrosineNutraceuticalPhase 4, Phase 2, Phase 1699
2
Doxorubicinapproved, investigationalPhase 3, Phase 1, Phase 2175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
3
Paclitaxelapproved, vet_approvedPhase 3, Phase 1286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
4
Trastuzumabapproved, investigationalPhase 3, Phase 1784180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
5
EpirubicinapprovedPhase 339456420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
6
Cyclophosphamideapproved, investigationalPhase 3293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
7
FluorouracilapprovedPhase 3185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
8
PertuzumabapprovedPhase 3127145040-37-5, 380610-27-52540
Synonyms:
2C4 Antibody
380610-27-5
D05446
Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
LS-185920
MOAB 2C4
MOAB2C4
Monoclonal Antibody 2C4
 
Omnitarg
Perjeta
Pertuzumab
Pertuzumab (USAN/INN)
Pertuzumab (genetical recombination)
Pertuzumab (genetical recombination) (JAN)
pertuzumab
rhuMAb 2C4
rhuMAb-2C4
9
DoxilApproved June 1999Phase 3, Phase 1, Phase 2175131703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
10
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 1, Phase 21967114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
11Antibiotics, AntitubercularPhase 3, Phase 2, Phase 17180
12Anti-Bacterial AgentsPhase 3, Phase 2, Phase 111226
13Immunosuppressive AgentsPhase 3, Phase 2, Phase 113086
143-IodobenzylguanidinePhase 369
15RadiopharmaceuticalsPhase 3514
16Calcium, DietaryPhase 3, Phase 1, Phase 25713
17Hormone AntagonistsPhase 3, Phase 2, Phase 113180
18HormonesPhase 3, Phase 2, Phase 114415
19Cinacalcet HydrochloridePhase 371
20Topoisomerase InhibitorsPhase 3, Phase 1, Phase 25069
21Antimitotic AgentsPhase 3, Phase 1, Phase 25657
22Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 2, Phase 113168
23Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 17361
24Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 15602
25Antineoplastic Agents, AlkylatingPhase 3, Phase 2, Phase 14603
26AntimetabolitesPhase 3, Phase 2, Phase 112054
27Alkylating AgentsPhase 3, Phase 2, Phase 14827
28Albumin-Bound PaclitaxelPhase 3, Phase 12864
29Calcimimetic AgentsPhase 371
30taxanePhase 3354
31Chelating AgentsPhase 31423
32Antirheumatic AgentsPhase 3, Phase 1, Phase 210956
33Ado-trastuzumab emtansinePhase 368
34MaytansinePhase 375
35
EverolimusapprovedPhase 2, Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
36
LoperamideapprovedPhase 1, Phase 214553179-11-63955
Synonyms:
2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
34552-83-5 (mono-hydrochloride)
4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide
4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
5-21-02-00379 (Beilstein Handbook Reference)
53179-11-6
AB00053697
AC1L1H38
AKOS000573892
Apo-Loperamide
BAS 01889668
BPBio1_000274
BRD-K61250553-001-02-9
BRD-K61250553-003-05-8
BRN 1558273
BSPBio_000248
BSPBio_001381
BSPBio_002769
Bio1_000082
Bio1_000571
Bio1_001060
Bio2_000101
Bio2_000581
C07080
C29H33ClN2O2
CAS-34552-83-5
CBiol_001796
CHEBI:162259
CHEBI:6532
CHEMBL841
CID3955
D08144
DB00836
Diamide (TN)
Diarr-Eze
DivK1c_000215
EINECS 258-416-5
HMS1791F03
HMS1989F03
HMS2089C13
IDI1_000215
IDI1_033851
Imodium A-D
Imodium A-D Caplets
Ioperamide
KBio1_000215
KBio2_000101
KBio2_000854
KBio2_002669
KBio2_003422
KBio2_005237
KBio2_005990
KBio3_000201
 
KBio3_000202
KBio3_001989
KBioGR_000101
KBioGR_001685
KBioSS_000101
KBioSS_000854
Kaopectate II
L000709
LS-114352
Lopac-L-4762
Lopac0_000708
Loperacap
Loperamid
Loperamida
Loperamida [INN-Spanish]
Loperamide (INN)
Loperamide Monohydrochloride
Loperamide [INN:BAN]
Loperamide hydrochloride
Loperamidum
Loperamidum [INN-Latin]
Lopéramide
Maalox Anti-Diarrheal
MolPort-001-969-016
NCGC00015608-01
NCGC00015608-08
NCGC00016828-01
NCGC00024818-01
NCGC00024818-02
NCGC00024818-03
NCGC00024818-04
NCGC00024818-05
NINDS_000215
Nu-Loperamide
Oprea1_109220
PMS-Loperamide
Pepto Diarrhea Control
Prestwick0_000144
Prestwick1_000144
Prestwick2_000144
Prestwick3_000144
R-18553
Rho-Loperamide
SPBio_001816
SPBio_002187
ST095179
Spectrum2_001738
Spectrum3_001015
Spectrum4_001143
Spectrum5_001374
Spectrum_000374
Tocris-0840
UNII-6X9OC3H4II
loperamide
nchembio.559-comp8
nchembio.79-comp7
37
Miconazoleapproved, investigational, vet_approvedPhase 2, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
38
Sirolimusapproved, investigationalPhase 2, Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
39
Capecitabineapproved, investigationalPhase 2, Phase 11342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
40
Vorinostatapproved, investigationalPhase 2247149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
41
Sunitinibapproved, investigationalPhase 2510341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
42
LenvatinibapprovedPhase 262417716-92-8
Synonyms:
4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide
 
E7080
Lenvatinib Mesylate
lenvatinib
43
Irinotecanapproved, investigationalPhase 2112397682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
44
Histamineapproved, investigationalPhase 1, Phase 2105075614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-(4-imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
4-imidazoleethylamine
5-Imidazoleethylamine
5-imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminoethylglyoxaline
beta-aminoethylimidazole
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
45
LenograstimapprovedPhase 1, Phase 21220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
46
Panobinostatapproved, investigationalPhase 2135404950-80-76918837
Synonyms:
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
404950-80-7
AC1OCFY8
AKOS005146046
C496932
CHEMBL483254
CID6918837
EC-000.2287
FT-0083488
Faridak
 
LBH 589
LBH-589
LBH-589B
LBH589
MolPort-005-933-338
NVP-LBH-589
NVP-LBH589
Panobinostat
Panobinostat, NVP-LBH589, LBH589
S1030_Selleck
ZINC22010649
nchembio.313-comp11
panobinostat
47
Gefitinibapproved, investigationalPhase 2361184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
48
Octreotideapproved, investigationalPhase 2, Phase 122383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
49
PancrelipaseapprovedPhase 2, Phase 197053608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
PA
 
Pancreatic alpha-amylase precursor
Pancrelipase (amylase
lipase
protease)
50
Axitinibapproved, investigationalPhase 2109319460-85-06450551
Synonyms:
319460-85-0
790713-39-2
AC-1539
AC1O51X3
AG 013736
AG-013736
AG-013736, Axitinib
AG-13736
AG013736
Axitinib
C503983
CID6450551
 
EC-000.2322
I14-1971
INLYTA
Inlyta
MolPort-006-392-413
N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
S1005_Selleck
ST51054130
UNII-C9LVQ0YUXG
ZINC03816287
axitinib
axitinibum

Interventional clinical trials:

(show top 50)    (show all 115)
idNameStatusNCT IDPhase
1Radiolabeled Molecules for Medullary Thyroid CancerRecruitingNCT01915485Phase 4
2A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerRecruitingNCT01896479Phase 4
3To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerActive, not recruitingNCT01496313Phase 4
4123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine TumorsUnknown statusNCT01373736Phase 3
5Cinacalcet to Treat Familial Primary HyperparathyroidismCompletedNCT00325104Phase 3
6Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)RecruitingNCT02586350Phase 2, Phase 3
7Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid CancerActive, not recruitingNCT00704730Phase 3
8An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerActive, not recruitingNCT00410761Phase 3
9Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib TreatmentActive, not recruitingNCT01298323Phase 3
10A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Active, not recruitingNCT01966471Phase 3
11The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid CancerUnknown statusNCT01739634Phase 1, Phase 2
12Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid CancerUnknown statusNCT01118065Phase 2
13SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid CancerCompletedNCT01625520Phase 2
14Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid CarcinomaCompletedNCT01661179Phase 1, Phase 2
15Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid CarcinomaCompletedNCT00467506Phase 2
16A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)CompletedNCT00923247Phase 1, Phase 2
17Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma PatientsCompletedNCT02114658Phase 2
18ImmunoTEP for Patients With Medullary Thyroid Carcinoma.CompletedNCT01730638Phase 1, Phase 2
19A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerCompletedNCT00358956Phase 2
20Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid CancerCompletedNCT00004048Phase 1, Phase 2
21Trial of LBH589 in Metastatic Thyroid CancerCompletedNCT01013597Phase 2
22Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid CancerCompletedNCT00100828Phase 2
23Thalidomide in Treating Patients With Thyroid CancerCompletedNCT00026533Phase 2
24Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid CancerCompletedNCT00519896Phase 2
25Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid CancerCompletedNCT00118248Phase 2
26Thyroid Cancer and SunitinibCompletedNCT00510640Phase 2
27Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid CancerCompletedNCT00654238Phase 2
28Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by HistologyCompletedNCT00784303Phase 2
29A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid CancerCompletedNCT00121628Phase 2
30Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid CancerCompletedNCT00124527Phase 2
31Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid CancerCompletedNCT00134043Phase 2
32Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine TherapyCompletedNCT00095836Phase 2
33Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid CancerCompletedNCT01164176Phase 2
34Capecitabine and Temozolomide for Neuroendocrine CancersCompletedNCT00869050Phase 2
35Sunitinib Malate in Patients With Non-Clear Cell Renal Cell CancerCompletedNCT00465179Phase 2
36Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
37Combination Chemotherapy and Tamoxifen in Treating Patients With Solid TumorsCompletedNCT00002608Phase 2
38Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerCompletedNCT00096083Phase 2
39Study Of AG-013736 In Patients With 131I-Refractory Thyroid CancerCompletedNCT00389441Phase 2
40Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerRecruitingNCT03072160Phase 2
41GI-6207 for Advanced Medullary Thyroid CancerRecruitingNCT01856920Phase 2
42Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid CarcinomaRecruitingNCT02614495Phase 2
43Nintedanib(BIBF1120) in Thyroid CancerRecruitingNCT01788982Phase 2
44A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid CancerRecruitingNCT02657551Phase 2
45A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial SarcomaRecruitingNCT02601950Phase 2
46Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical StudyRecruitingNCT02084732Phase 2
47Vandetanib in Advanced NSCLC With RET RearrangementRecruitingNCT01823068Phase 2
48Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityRecruitingNCT01639508Phase 2
49Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate CancerRecruitingNCT01683994Phase 1, Phase 2
50PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung CancersRecruitingNCT02936323Phase 1, Phase 2

Search NIH Clinical Center for Medullary Thyroid Carcinoma, Familial


Cochrane evidence based reviews: thyroid cancer, medullary

Genetic Tests for Medullary Thyroid Carcinoma, Familial

About this section

Genetic tests related to Medullary Thyroid Carcinoma, Familial:

id Genetic test Affiliating Genes
1 Medullary Thyroid Carcinoma27
2 Familial Medullary Thyroid Carcinoma27 24

Anatomical Context for Medullary Thyroid Carcinoma, Familial

About this section

MalaCards organs/tissues related to Medullary Thyroid Carcinoma, Familial:

36
Thyroid, Endothelial, Liver, Lung, Testes

Publications for Medullary Thyroid Carcinoma, Familial

About this section

Articles related to Medullary Thyroid Carcinoma, Familial:

idTitleAuthorsYear
1
RET Germline Mutations Identified by Exome Sequencing in a Chinese Multiple Endocrine Neoplasia Type 2A/Familial Medullary Thyroid Carcinoma Family. (21655256)
2011
2
Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families. (9436479)
1997
3
A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. (7835899)
1994
4
Medullary thyroid carcinoma--familial or sporadic disease?]. (7974404)
1994

Variations for Medullary Thyroid Carcinoma, Familial

About this section

UniProtKB/Swiss-Prot genetic disease variations for Medullary Thyroid Carcinoma, Familial:

70 (show all 30)
id Symbol AA change Variation ID SNP ID
1RETp.Cys609TyrVAR_006306rs77939446
2RETp.Cys611TrpVAR_006308rs80069458
3RETp.Cys618ArgVAR_006311rs76262710
4RETp.Cys618PheVAR_006312rs79781594
5RETp.Cys618SerVAR_006313rs79781594
6RETp.Cys618TyrVAR_006314rs79781594
7RETp.Cys620GlyVAR_006315rs77316810
8RETp.Cys620ArgVAR_006316rs77316810
9RETp.Cys620SerVAR_006317rs77503355
10RETp.Cys620PheVAR_006318rs77503355
11RETp.Cys630PheVAR_006320rs377767405
12RETp.Cys634TyrVAR_006325rs75996173
13RETp.Cys634ArgVAR_006326rs75076352
14RETp.Cys634SerVAR_006327rs75076352
15RETp.Cys634TrpVAR_006328rs77709286
16RETp.Glu768AspVAR_006335rs78014899
17RETp.Val804LeuVAR_006336rs79658334
18RETp.Val804MetVAR_006337rs79658334
19RETp.Met918ThrVAR_006342rs74799832
20RETp.Thr946MetVAR_006345
21RETp.Cys611GlyVAR_009472rs377767391
22RETp.Cys630SerVAR_009477rs377767405
23RETp.Cys630TyrVAR_009478rs377767405
24RETp.Leu790PheVAR_009482rs75030001
25RETp.Tyr791PheVAR_009483rs77724903
26RETp.Ser891AlaVAR_009486rs75234356
27RETp.Arg844LeuVAR_011582rs55947360
28RETp.Ala639GlyVAR_012743
29RETp.Ala641GlyVAR_012744
30RETp.Ser922PheVAR_012745rs377767432

Clinvar genetic disease variations for Medullary Thyroid Carcinoma, Familial:

5 (show all 28)
id Gene Variation Type Significance SNP ID Assembly Location
1RETNM_ 020975.4(RET): c.1901G> A (p.Cys634Tyr)SNVPathogenic/ Likely pathogenicrs75996173GRCh37Chr 10, 43609949: 43609949
2RETNM_ 020630.4(RET): c.1901G> T (p.Cys634Phe)SNVPathogenicrs75996173GRCh37Chr 10, 43609949: 43609949
3RETNM_ 020975.4(RET): c.1853G> C (p.Cys618Ser)SNVPathogenicrs79781594GRCh37Chr 10, 43609097: 43609097
4RETNM_ 020630.4(RET): c.1859G> A (p.Cys620Tyr)SNVPathogenic/ Likely pathogenicrs77503355GRCh37Chr 10, 43609103: 43609103
5RETNM_ 020975.4(RET): c.1900T> C (p.Cys634Arg)SNVPathogenic/ Likely pathogenicrs75076352GRCh37Chr 10, 43609948: 43609948
6RETNM_ 020630.4(RET): c.1902C> G (p.Cys634Trp)SNVPathogenic/ Likely pathogenicrs77709286GRCh37Chr 10, 43609950: 43609950
7RETNM_ 020975.4(RET): c.2753T> C (p.Met918Thr)SNVPathogenic/ Likely pathogenicrs74799832GRCh37Chr 10, 43617416: 43617416
8RETNM_ 020630.4(RET): c.1859G> T (p.Cys620Phe)SNVPathogenicrs77503355GRCh37Chr 10, 43609103: 43609103
9RETNM_ 020630.4(RET): c.1852T> C (p.Cys618Arg)SNVPathogenic/ Likely pathogenicrs76262710GRCh37Chr 10, 43609096: 43609096
10RETNM_ 020630.4(RET): c.2304G> C (p.Glu768Asp)SNVPathogenic/ Likely pathogenicrs78014899GRCh37Chr 10, 43613840: 43613840
11RETNM_ 020975.4(RET): c.1826G> A (p.Cys609Tyr)SNVPathogenic/ Likely pathogenicrs77939446GRCh37Chr 10, 43609070: 43609070
12RETNM_ 020975.4(RET): c.2370G> C (p.Leu790Phe)SNVPathogenicrs75030001GRCh37Chr 10, 43613906: 43613906
13RETNM_ 020630.4(RET): c.1586_ 1594dupAGGAGTGTG (p.Cys531_ Gly532insGluGluCys)duplicationPathogenicrs377767434GRCh37Chr 10, 43607610: 43607618
14RETNM_ 020630.4(RET): c.1859G> C (p.Cys620Ser)SNVPathogenicrs77503355GRCh37Chr 10, 43609103: 43609103
15RETNM_ 020630.4(RET): c.1825T> C (p.Cys609Arg)SNVPathogenicrs77558292GRCh37Chr 10, 43609069: 43609069
16RETNM_ 020630.4(RET): c.2410G> T (p.Val804Leu)SNVPathogenicrs79658334GRCh37Chr 10, 43614996: 43614996
17RETNM_ 020630.4(RET): c.1597G> T (p.Gly533Cys)SNVPathogenicrs75873440GRCh37Chr 10, 43607621: 43607621
18RETNM_ 020975.4(RET): c.2671T> G (p.Ser891Ala)SNVPathogenic/ Likely pathogenicrs75234356GRCh37Chr 10, 43615592: 43615592
19RETNM_ 020975.4(RET): c.1853G> A (p.Cys618Tyr)SNVPathogenic/ Likely pathogenicrs79781594GRCh37Chr 10, 43609097: 43609097
20RETNM_ 020630.4(RET): c.1888T> C (p.Cys630Arg)SNVPathogenic/ Likely pathogenicrs377767404GRCh37Chr 10, 43609936: 43609936
21RETNM_ 020630.4(RET): c.2735G> C (p.Arg912Pro)SNVPathogenicrs78347871GRCh37Chr 10, 43617398: 43617398
22RETNM_ 020975.4(RET): c.2410G> A (p.Val804Met)SNVPathogenicrs79658334GRCh37Chr 10, 43614996: 43614996
23RETNM_ 020630.4(RET): c.1834_ 1860del27 (p.Phe612_ Cys620del)deletionLikely pathogenicrs121913313GRCh37Chr 10, 43609078: 43609104
24RETNM_ 020975.4(RET): c.1894_ 1899delGAGCTG (p.Glu632_ Leu633del)deletionLikely pathogenicrs121913312GRCh37Chr 10, 43609942: 43609947
25RETNM_ 020630.4(RET): c.2692_ 2703delGATGTTTATGAA (p.Asp898_ Glu901del)deletionLikely pathogenicrs121913309GRCh37Chr 10, 43615613: 43615624
26RETNM_ 020630.4(RET): c.2410G> C (p.Val804Leu)SNVPathogenic/ Likely pathogenicrs79658334GRCh37Chr 10, 43614996: 43614996
27RETNM_ 020975.4(RET): c.2647_ 2648delGCinsTT (p.Ala883Phe)indelPathogenic/ Likely pathogenicrs377767429GRCh37Chr 10, 43615568: 43615569
28KRASNM_ 033360.3(KRAS): c.182A> T (p.Gln61Leu)SNVPathogenic/ Likely pathogenicrs121913240GRCh37Chr 12, 25380276: 25380276

Cosmic variations for Medullary Thyroid Carcinoma, Familial:

8 (show top 50)    (show all 59)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM965RETthyroid,NS,carcinoma,medullary carcinomac.2753T>Cp.M918T36
2COSM29806RETthyroid,NS,carcinoma,medullary carcinomac.1888T>Gp.C630G36
3COSM29805RETthyroid,NS,carcinoma,medullary carcinomac.1859G>Cp.C620S36
4COSM552KRASthyroid,NS,carcinoma,medullary carcinomac.182A>Gp.Q61R36
5COSM476BRAFthyroid,NS,carcinoma,medullary carcinomac.1799T>Ap.V600E36
6COSM966RETthyroid,NS,carcinoma,medullary carcinomac.1900T>Cp.C634R36
7COSM499HRASthyroid,NS,carcinoma,medullary carcinomac.182A>Gp.Q61R36
8COSM29803RETthyroid,NS,carcinoma,medullary carcinomac.1852T>Cp.C618R36
9COSM584NRASthyroid,NS,carcinoma,medullary carcinomac.182A>Gp.Q61R36
10COSM486HRASthyroid,NS,carcinoma,medullary carcinomac.37G>Cp.G13R36
11COSM520KRASthyroid,NS,carcinoma,medullary carcinomac.35G>Tp.G12V36
12COSM3437784RETthyroid,NS,carcinoma,medullary carcinomac.2206G>Ap.G736R36
13COSM1732634HRASthyroid,NS,carcinoma,medullary carcinomac.216G>Ap.M72I36
14COSM518KRASthyroid,NS,carcinoma,medullary carcinomac.34G>Cp.G12R36
15COSM974RETthyroid,NS,carcinoma,medullary carcinomac.1901G>Ap.C634Y36
16COSM498HRASthyroid,NS,carcinoma,medullary carcinomac.182A>Tp.Q61L36
17COSM549KRASthyroid,NS,carcinoma,medullary carcinomac.181C>Ap.Q61K36
18COSM19900KRASthyroid,NS,carcinoma,medullary carcinomac.437C>Tp.A146V36
19COSM133167RETthyroid,NS,carcinoma,medullary carcinomac.2647G>Tp.A883S36
20COSM517KRASthyroid,NS,carcinoma,medullary carcinomac.34G>Ap.G12S36
21COSM975RETthyroid,NS,carcinoma,medullary carcinomac.1902C>Gp.C634W36
22COSM4170226RETthyroid,NS,carcinoma,medullary carcinomac.1946C>Tp.S649L36
23COSM496HRASthyroid,NS,carcinoma,medullary carcinomac.181C>Ap.Q61K36
24COSM21338RETthyroid,NS,carcinoma,medullary carcinomac.2304G>Cp.E768D36
25COSM553KRASthyroid,NS,carcinoma,medullary carcinomac.182A>Tp.Q61L36
26COSM482HRASthyroid,NS,carcinoma,medullary carcinomac.34G>Cp.G12R36
27COSM963RETthyroid,NS,carcinoma,medullary carcinomac.2701G>Ap.E901K36
28COSM249792RETthyroid,NS,carcinoma,medullary carcinomac.2041C>Tp.Q681*36
29COSM5598719RETthyroid,NS,carcinoma,medullary carcinomac.2137G>Ap.E713K36
30COSM960RETthyroid,NS,carcinoma,medullary carcinomac.2650G>Ap.E884K36
31COSM14320VHLthyroid,NS,carcinoma,medullary carcinomac.233A>Tp.N78I36
32COSM959RETthyroid,NS,carcinoma,medullary carcinomac.2627C>Tp.A876V36
33COSM961RETthyroid,NS,carcinoma,medullary carcinomac.2723G>Ap.R908K36
34COSM20889RETthyroid,NS,carcinoma,medullary carcinomac.2761G>Ap.E921K36
35COSM964RETthyroid,NS,carcinoma,medullary carcinomac.1888T>Cp.C630R36
36COSM583NRASthyroid,NS,carcinoma,medullary carcinomac.182A>Tp.Q61L36
37COSM528KRASthyroid,NS,carcinoma,medullary carcinomac.37G>Ap.G13S36
38COSM27159KRASthyroid,NS,carcinoma,medullary carcinomac.187G>Ap.E63K36
39COSM29804RETthyroid,NS,carcinoma,medullary carcinomac.1858T>Cp.C620R36
40COSM489HRASthyroid,NS,carcinoma,medullary carcinomac.38G>Tp.G13V36
41COSM1237679MDC1thyroid,NS,carcinoma,medullary carcinomac.6266C>Ap.T2089N36
42COSM304967HRASthyroid,NS,carcinoma,medullary carcinomac.351G>Tp.K117N36
43COSM971RETthyroid,NS,carcinoma,medullary carcinomac.2296C>Tp.P766S36
44COSM249789RETthyroid,NS,carcinoma,medullary carcinomac.2117T>Cp.V706A36
45COSM481HRASthyroid,NS,carcinoma,medullary carcinomac.34G>Tp.G12C36
46COSM1247975CDKN2Cthyroid,NS,carcinoma,medullary carcinomac.214G>Ap.A72T36
47COSM980RETthyroid,NS,carcinoma,medullary carcinomac.1853G>Ap.C618Y36
48COSM958RETthyroid,NS,carcinoma,medullary carcinomac.2242G>Tp.G748C36
49COSM918118RETthyroid,NS,carcinoma,medullary carcinomac.2038G>Ap.A680T36
50COSM4445256CDKN2Cthyroid,NS,carcinoma,medullary carcinomac.235A>Gp.R79G36

Copy number variations for Medullary Thyroid Carcinoma, Familial from CNVD:

6 (show all 35)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
13202813269524532893524Copy numberMedullary thyroid carcinoma
23275713912458739304462Copy numberMedullary thyroid carcinoma
33526916189229162734672Copy numberMedullary thyroid carcinoma
4372731886774010433514Copy numberMedullary thyroid carcinoma
55054711118321536118342357Copy numberMedullary thyroid carcinoma
6722061276962758062485Copy numberMedullary thyroid carcinoma
775351131925496619420048Copy numberMedullary thyroid carcinoma
884518143052569730878740Copy numberMedullary thyroid carcinoma
994252156442077264430751Copy numberMedullary thyroid carcinoma
1098948162192540021925459Copy numberMedullary thyroid carcinoma
11109449172610845826265366Copy numberMedullary thyroid carcinoma
12110763173421715834217217Copy numberMedullary thyroid carcinoma
13120216182201831622032151Copy numberMedullary thyroid carcinoma
141269581922692519692685Copy numberMedullary thyroid carcinoma
15157094211011789810144936Copy numberMedullary thyroid carcinoma
16157510211766740417854835Copy numberMedullary thyroid carcinoma
17158515213365867433833374Copy numberMedullary thyroid carcinoma
18159066213955368939729222Copy numberMedullary thyroid carcinoma
19162875222273119630657843Copy numberMedullary thyroid carcinoma
20164568223769696437715431Copy numberMedullary thyroid carcinoma
21164574223771866941848706Copy numberMedullary thyroid carcinoma
221726693185265380185329933Copy numberMedullary thyroid carcinoma
2317617334701888450073930Copy numberMedullary thyroid carcinoma
2418797545687463657555635Copy numberMedullary thyroid carcinoma
251936805132290783132440481Copy numberMedullary thyroid carcinoma
2620056555643706556573822Copy numberMedullary thyroid carcinoma
2720142256886871370422356Copy numberMedullary thyroid carcinoma
2820157857062271570698853Copy numberMedullary thyroid carcinoma
2921528167418022674456183Copy numberMedullary thyroid carcinoma
302223667151686560152069929Copy numberMedullary thyroid carcinoma
3122622175569592457405095Copy numberMedullary thyroid carcinoma
3222776477188707675407752Copy numberMedullary thyroid carcinoma
332455649109184070109357673Copy numberMedullary thyroid carcinoma
3424982391898376819243114Copy numberMedullary thyroid carcinoma
35254446966101606848238Copy numberMedullary thyroid carcinoma

Expression for genes affiliated with Medullary Thyroid Carcinoma, Familial

About this section
Search GEO for disease gene expression data for Medullary Thyroid Carcinoma, Familial.

Pathways for genes affiliated with Medullary Thyroid Carcinoma, Familial

About this section

GO Terms for genes affiliated with Medullary Thyroid Carcinoma, Familial

About this section

Cellular components related to Medullary Thyroid Carcinoma, Familial according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00055768.9CALCA, CALCB, CEACAM5, CHGA, ESR2, GAST
2integral component of plasma membraneGO:00058878.2CCKBR, CEACAM5, EDNRB, NTRK1, RET, SSTR1

Biological processes related to Medullary Thyroid Carcinoma, Familial according to GeneCards Suite gene sharing:

(show all 22)
idNameGO IDScoreTop Affiliating Genes
1detection of temperature stimulus involved in sensory perception of painGO:005096510.9CALCA, NTRK1
2peristalsisGO:003043210.8GDNF, SSTR2
3posterior midgut developmentGO:000749710.8EDNRB, RET
4enteric nervous system developmentGO:004848410.6EDNRB, GDNF, RET
5neural crest cell migrationGO:000175510.6EDNRB, GDNF, RET
6response to painGO:004826510.6CALCA, EDNRB, RET
7regulation of blood pressureGO:000821710.5CALCA, CHGA, EDNRB
8MAPK cascadeGO:000016510.5GDNF, GFRA1, MEN1, RET
9neuropeptide signaling pathwayGO:000721810.3CALCA, SSTR1, SSTR2
10response to nutrientGO:000758410.3SST, SSTR1, SSTR2
11axon guidanceGO:000741110.3GDNF, GFRA1, NKX2-1, NTRK1, RET
12forebrain developmentGO:003090010.3NKX2-1, SSTR1, SSTR2
13nervous system developmentGO:000739910.2EDNRB, GDNF, GFRA1, NTRK1, RET
14G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerGO:000718710.2SSTR1, SSTR2, SSTR5
15sympathetic nervous system developmentGO:004848510.1GDNF, NTRK1
16digestionGO:000758610.1CCKBR, SST, SSTR1, SSTR2
17cell-cell signalingGO:000726710.0CALCA, ESR2, SST, SSTR1, SSTR2
18cell surface receptor signaling pathwayGO:00071669.9CCKBR, EDNRB, GFRA1, SST, SSTR1
19somatostatin signaling pathwayGO:00381709.8SSTR1, SSTR2, SSTR5
20negative regulation of cell proliferationGO:00082859.6MEN1, NTRK1, SST, SSTR1, SSTR2, SSTR5
21G-protein coupled receptor signaling pathwayGO:00071869.1CCKBR, EDNRB, GAST, SST, SSTR1, SSTR2
22signal transductionGO:00071657.7CALCB, CCKBR, EDNRB, ESR2, GAST, GDNF

Molecular functions related to Medullary Thyroid Carcinoma, Familial according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1hormone activityGO:00051799.8CALCA, GAST, SST, TG
2neuropeptide bindingGO:00429239.6SSTR1, SSTR2, SSTR5
3somatostatin receptor activityGO:00049949.4SSTR1, SSTR2, SSTR5

Sources for Medullary Thyroid Carcinoma, Familial

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet